Market Place
Sourcing Support
Cornerstone Pharmaceuticals Initiates Phase 1 Trial of CPI-613® (devimistat)
28 Sep 2022 //
GLOBENEWSWIRE
Cornerstone Pharma to Present Data on CPI-613 From Open-Label PI Study at ESMO
27 Jun 2022 //
GLOBENEWSWIRE
Cornerstone Pharma Announces Published Data on CPI-613 as an Effective Approach
16 Jun 2022 //
GLOBENEWSWIRE
EMA Grants ODD to Cornerstone`s CPI-613 (Devimistat) for Biliary Tract Cancer
24 May 2022 //
GLOBENEWSWIRE
Rafael Completes Enrollment in Phase 2 Trial of CPI-613 in biliary tract cancer
18 Jan 2022 //
GLOBENEWSWIRE
Rafael Pharma Completes Dose Escalation in APOLLO 613 Phase 1/2 Trial of CPI-613
06 Jan 2022 //
GLOBENEWSWIRE
Rafael Begins Enrollment in Phase 1/2 Trial of CPI-613 in Clear Cell Sarcoma
11 Nov 2021 //
GLOBENEWSWIRE
Telecom tycoon`s phase 3 pancreatic cancer bet flames out
29 Oct 2021 //
MARKETWATCH
Rafael Holdings Provides Update on Rafael Pharmaceuticals’ Two Phase 3 Trials
28 Oct 2021 //
GLOBENEWSWIRE
Rafael Announces Positive Data on (ARMADA 2000) of CPI-613
01 Jul 2021 //
GLOBENEWSWIRE
Rafael Pharma to Present Pancreatic & Biliary Tract Cancer Data on CPI-613
30 Jun 2021 //
GLOBENEWSWIRE
FDA Grants Rafael Pharmaceuticals Orphan Drug Designation for CPI-613
29 Jun 2021 //
GLOBENEWSWIRE
FDA Grants Fast Track Designation to Devimistat for Treatment of AML
15 Dec 2020 //
CANCERNETWORK
FDA grants orphan status to Rafael Pharmaceuticals cancer drug
10 Dec 2020 //
OUTSOURCING-PHARMA
Rafael Pharmaceuticals Partners with Sara’s Cure and SARC
01 Dec 2020 //
GLOBENEWSWIRE
Rafael Receives FDA Fast Track Designation for CPI-613® (devimistat)
10 Nov 2020 //
GLOBENEWSWIRE
FDA Grants Orphan Drug Designation to Devimistat for Soft Tissue Sarcoma
30 Oct 2020 //
TARGETEDONC
Rafael Crosses Enrollment of 100th Patient Ph3Trial (ARMADA 2000) of CPI-613®
27 Oct 2020 //
GLOBENEWSWIRE
Rafael Achieves Target Enrollment of 500 Patients in Ph 3 Trial (AVENGER 500)
06 Aug 2020 //
GLOBENEWSWIRE
Rafael Crosses Midpoint of Enrollment to First Interim Analysis Ph 3 Trial
21 Jul 2020 //
GLOBENEWSWIRE
Rafael to Present Phase 1 Data on CPI-613® (Devimistat) in Patients
26 May 2020 //
GLOBENEWSWIRE
Rafael Announces In Vivo Study to Evaluate the Effects of CPI-613® (Devimistat)
07 May 2020 //
GLOBENEWSWIRE
Generex Subsidiary NuGenerex Immuno-Oncology Announces AE37 Phase IIb
28 Apr 2020 //
GLOBENEWSWIRE
Rafael Receives Approvals to Open Trial Sites in India and Canada Ph3 Trial
23 Apr 2020 //
GLOBENEWSWIRE
Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.